Up-regulation of RhoGDI2 in Human Breast Cancer and Its Prognostic Implications.
- Author:
Hyeong Gon MOON
1
;
Sang Ho JEONG
;
Young Tae JU
;
Chi Young JEONG
;
Jong Sil LEE
;
Young Joon LEE
;
Soon Chan HONG
;
Sang Kyung CHOI
;
Woo Song HA
;
Soon Tae PARK
;
Eun Jung JUNG
Author Information
1. Department of Surgery, Seoul National University Hospital, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Breast neoplasms;
RhoGDI2 protein;
Prognosis;
Neoplasm metastasis;
Proteomics
- MeSH:
Breast;
Breast Neoplasms;
Cohort Studies;
Disease-Free Survival;
Humans;
Immunohistochemistry;
Lymph Nodes;
Neoplasm Metastasis;
Prognosis;
Proteins;
Proteomics;
rho Guanine Nucleotide Dissociation Inhibitor beta;
Up-Regulation;
Urinary Bladder Neoplasms
- From:Cancer Research and Treatment
2010;42(3):151-156
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Recent research has identified many genes and proteins that play specific roles in the process of systemic metastasis in various types of cancer. Rho GDP dissociation inhibitor 2 (RhoGDI2) has been shown to inhibit metastasis in human bladder cancer, but its role in breast cancer is controversial. MATERIALS AND METHODS: We examined the regulation and clinical significance of RhoGDI2 in Korean breast cancer patients by using proteomic approaches. RESULTS: By using a proteomic approach, we observed an increased expression of RhoGDI2 in human breast cancer tissues when compared to that of the normal breast tissues, and we validated its up-regulation in an independent cohort of 8 breast cancer patients. The clinical implication of a RhoGDI2 expression was investigated in 57 breast cancer patients by performing immunohistochemistry. RhoGDI2 did not show a significant association with the tumor size, lymph node metastasis, the histologic grade or the hormone receptor status. However, the patients with RhoGDI2-expressing tumors had significantly shorter disease-free survival (p=0.043; hazard ratio, 3.87) and distant metastasis-free survival (p=0.039; hazard ratio, 5.15). CONCLUSION: Our results demonstrated a potential role of RhoGDI2 as a poor prognostic marker as well as a potential therapeutic target. The pro-metastatic nature of RhoGDI2 shown in our study may indicate its organ-specific role in cancer metastasis.
